Literature DB >> 5547282

Skin capillary blood flow in scleroderma.

E C LeRoy, J A Downey, P J Cannon.   

Abstract

Skin blood flow was measured by the clearance of radioactive xenon ((133)Xe) injected intracutaneously in eight patients with scleroderma and nine control subjects under conditions of controlled temperature and humidity. Scleroderma patients, on being cooled 1 hr at 18 degrees C, had a rate constant of (133)Xe clearance from the dorsal finger skin which was 0.04 +/-0.07 min(-1) (mean +/-SD), compared with 0.23 +/-0.15 min(-1) in normal subjects (P < 0.005). The corresponding mean cutaneous blood flows were 2.9 ml/100 g per min in the scleroderma patients and 16.4 ml/100 g per min in normal subjects. After reflex warming by waterbath, clearance was similar in the two groups (0.33 +/-0.1 vs. 0.40 +/-0.09); these data suggest that diminished clearance in scleroderma patients on cooling resulted, at least in part, from functional or reversible interruption of the circulation. The skin temperatures of scleroderma patients after reflex warming remained lower than those of normal subjects, despite similar increases in sublingual temperatures. The dissociation of (133)Xe clearance and skin temperature in scleroderma patients (i.e. subnormal skin temperatures with normal (133)Xe clearance after reflex warming) suggests either abnormal thermal properties of scleroderma skin or selective vasoconstriction of the vessels which regulate heat exchange. The demonstrated interruption of the capillary circulation on cooling of the skin in patients with scleroderma may be important in the pathogenesis of this disorder. After oral pretreatment with guanethidine, five patients with scleroderma had increased (133)Xe clearance and calculated blood flow on cooling, rising to normal in three of these patients. The potential of this technique for the quantitative sequential evaluation of skin blood flow in subjects with scleroderma and for the evaluation of empirical therapy is suggested.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5547282      PMCID: PMC292008          DOI: 10.1172/JCI106565

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  16 in total

1.  MUSCLE BLOOD FLOW IN NORMAL MAN AND IN PATIENTS WITH INTERMITTENT CLAUDICATION EVALUATED BY SIMULTANEOUS XE-133 AND NA24 CLEARANCES.

Authors:  N A LASSEN
Journal:  J Clin Invest       Date:  1964-09       Impact factor: 14.808

2.  [Accelerometer for the registration of blood flow on surfaces].

Authors:  H HENSEL
Journal:  Pflugers Arch Gesamte Physiol Menschen Tiere       Date:  1959

3.  Collagen profile in various clinical conditions.

Authors:  E D Harris; A Sjoerdsma
Journal:  Lancet       Date:  1966-10-01       Impact factor: 79.321

4.  Nail-fold capillaries in connective-tissue disorders.

Authors:  I S Buchanan; D J Humpston
Journal:  Lancet       Date:  1968-04-20       Impact factor: 79.321

5.  Evidence of microvascular injury in scleroderma and systemic lupus erythematosus: quantitative study of the microvascular bed.

Authors:  W L Norton; E R Hurd; D C Lewis; M Ziff
Journal:  J Lab Clin Med       Date:  1968-06

6.  Epidermal diffusion barrier to 133Xe in man and studies of clearance of 133Xe by sweat.

Authors:  P Sejrsen
Journal:  J Appl Physiol       Date:  1968-02       Impact factor: 3.531

7.  Reserpine in Raynaud's disease and phenomenon. Short-term response to intra-arterial injection.

Authors:  J T Willerson; R H Thompson; P Hookman; J Herdt; J L Decker
Journal:  Ann Intern Med       Date:  1970-01       Impact factor: 25.391

8.  Suppression of Raynaud's phenomenon by methyldopa.

Authors:  D P Varadi; A M Lawrence
Journal:  Arch Intern Med       Date:  1969-07

9.  Solubility of krypton and xenon in blood, protein solutions, and tissue homogenates.

Authors:  S Y Yeh; R E Peterson
Journal:  J Appl Physiol       Date:  1965-09       Impact factor: 3.531

10.  Chemical synthesis of the dermis in scleroderma.

Authors:  R Fleischmajer; S Krol
Journal:  Proc Soc Exp Biol Med       Date:  1967-10
View more
  12 in total

1.  Raynaud's Phenomenon.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-06

Review 2.  Pathogenesis and treatment of Raynaud's phenomenon.

Authors:  J D Coffman
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

Review 3.  A vascular mechanistic approach to understanding Raynaud phenomenon.

Authors:  Nicholas A Flavahan
Journal:  Nat Rev Rheumatol       Date:  2014-12-23       Impact factor: 20.543

4.  Age-associated induction of cell membrane CD47 limits basal and temperature-induced changes in cutaneous blood flow.

Authors:  Natasha M Rogers; David D Roberts; Jeffrey S Isenberg
Journal:  Ann Surg       Date:  2013-07       Impact factor: 12.969

Review 5.  A Review of Raynaud's Disease.

Authors:  Katherine K Temprano
Journal:  Mo Med       Date:  2016 Mar-Apr

6.  In vivo photoacoustic microscopy of human cuticle microvasculature with single-cell resolution.

Authors:  Hsun-Chia Hsu; Lidai Wang; Lihong V Wang
Journal:  J Biomed Opt       Date:  2016-05-01       Impact factor: 3.170

Review 7.  Influence of vasospasm on visual function.

Authors:  P Gasser; J Flammer
Journal:  Doc Ophthalmol       Date:  1987-05       Impact factor: 2.379

8.  Effects of prostaglandin E1 on microvascular haemodynamics in progressive systemic sclerosis.

Authors:  M F Martin; J E Tooke
Journal:  Br Med J (Clin Res Ed)       Date:  1982-12-11

9.  Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis.

Authors:  M F Martin; P M Dowd; E F Ring; E D Cooke; P A Dieppe; J D Kirby
Journal:  Ann Rheum Dis       Date:  1981-08       Impact factor: 19.103

10.  Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: a double-blind trial.

Authors:  J J Belch; J Cormie; P Newman; M McLaren; J Barbenel; H Capell; P Leiberman; C D Forbes; C R Prentice
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.